24 February 2014 : Case report
Long-term complete remission of metastatic breast cancer induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor
Unusual clinical course, Unusual or unexpected effect of treatment, Unexpected drug reaction , Educational Purpose (only if useful for a systematic review or synthesis)Yoshihiro ShioiABDEF, Masahiro KashiwabaADEF, Toru InabaABD, Hideaki KomatsuB, Tamotsu SugaiBD, Go WakabayashiA
Am J Case Rep 2014; 15:85-89
Background: The efficacy of third-generation aromatase inhibitors for hormone receptor-positive postmenopausal metastatic breast cancer is well established. Although several clinical trials have reported incomplete cross-resistance between different aromatase inhibitors, few cases of complete responses of recurrent metastatic breast cancer occurring after substituting a second aromatase inhibitor have been reported. We here present a rare case of non-steroidal aromatase inhibitor-tolerant metastatic breast cancer with long-term complete remission following substitution of a steroidal aromatase inhibitor.
Case Report: We present the case of a 56-year-old Japanese woman who underwent right breast-conserving surgery for breast cancer, TNM staging T1, N0, M0, Stage I. She received adjuvant chemotherapy with 6 cycles of FEC100 and radiation therapy, and then began hormonal therapy with anastrozole. Twelve months postoperatively, computed tomography (CT) revealed multiple lung metastases. Exemestane was substituted for anastrozole. After 3 months of exemestane, CT showed that all lung metastases had completely resolved. Her complete response was maintained for 5 years: she died during a tsunami 6 years after the initial surgery.
Conclusions: Substitution of a steroidal for a non-steroidal aromatase inhibitor produced a sustained complete remission in a patient with hormonal receptor-positive postmenopausal recurrent breast cancer.
Achieving complete response after switching from a non-steroidal to a steroidal aromatase inhibitor in a hormonal receptor-positive postmenopausal recurrent breast cancer contributed to a higher quality of life for the patient. Further investigation is needed to identify the predictors of long-term remission following such a switch.
Keywords: Neoplasm Metastasis, Breast Neoplasms - therapy, Aromatase Inhibitors
26 November 2021 : EditorialEditorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
Med Sci Monit In Press; DOI: 10.12659/MSM.935624
26 November 2021 : Case reportArteritic Anterior Ischemic Optic Neuropathy in the Course of Giant Cell Arteritis After COVID-19
Am J Case Rep In Press; DOI: 10.12659/AJCR.933471
26 October 2021 : Case reportProgressive Pulmonary Fibrosis After Non-Critical COVID-19: A Case Report
Am J Case Rep In Press; DOI: 10.12659/AJCR.933458
29 Nov 2021 : Case reportA 58-Year-Old Woman with Gallstones, Chronic Pancreatitis, and Pancreatic Pseudocyst Presenting with Pleura...
Am J Case Rep In Press; DOI: 10.12659/AJCR.934247
29 Nov 2021 : Case reportAcute Perforated Appendicitis Associated with Appendiceal Diverticulitis in a Young Man: A Case Report with...
Am J Case Rep In Press; DOI: 10.12659/AJCR.934838
26 Nov 2021 : Case reportA Case of Metaplastic Squamous Cell Carcinoma of the Breast that Showed a Pathological Complete Response Af...
Am J Case Rep In Press; DOI: 10.12659/AJCR.935035
Most Viewed Current Articles
15 Aug 2020 : Case reportA 57-Year-Old African American Man with Severe COVID-19 Pneumonia Who Responded to Supportive Photobiomodul...
Am J Case Rep 2020; 21:e926779
09 May 2019 : Case reportA Rare Case of Stage IV Basaloid Squamous Cell Cancer with Intrapulmonary and Brain Metastases
Am J Case Rep 2019; 20:664-667
13 Mar 2019 : Case reportDry Beriberi Due to Thiamine Deficiency Associated with Peripheral Neuropathy and Wernicke’s Encephalopathy...
Am J Case Rep 2019; 20:330-334